Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Deborah Wexler MD, MSc

Deborah J. Wexler MD, MSc

Associate Professor of Medicine, Harvard Medical School; Chief, Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts

Dr. Deborah J. Wexler is Associate Professor of Medicine at Harvard Medical School and Chief of the Massachusetts General Hospital Diabetes Unit.

Dr. Wexler’s research focuses on clinical effectiveness in type 2 diabetes. She has led multiple National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)– and Patient-Centered Outcomes Research Institute (PCORI)– funded projects that seek to improve the health and well-being of people with diabetes. Dr Wexler is on the editorial board of Diabetes Care, is a reviewer for multiple medical journals, and is an editor of NIDDK’s Diabetes in America.

She received her medical degree from Yale University School of Medicine, New Haven, Connecticut, and completed her internship, residency, and chief residency in internal medicine and fellowship in endocrinology at Massachusetts General Hospital in Boston.

Disclosures

  • Data monitoring committees: Novo Nordisk (for trials of oral semaglutide)

Recent Contributions to PracticeUpdate:

  1. 2024 Top Story in Diabetes: Efficacy of GLP-1 Receptor Agonists for Obesity-Related Complications
  2. Risk of Complications and Mortality Rates Among Individuals With Younger- vs Later-Onset Type 2 Diabetes
  3. Mineralocorticoid Receptor Antagonists and Reno-Protection
  4. Effect of Combination Treatment With GLP-1 Receptor Agonists and SGLT-2 Inhibitors on Incidence of Cardiovascular and Serious Renal Events
  5. Use of Rescue Insulin in the GRADE Study
  6. Comparative Effects of Randomized Second-Line Therapy for Type 2 Diabetes on Glycemic Control, Body Weight, and Hypoglycemia in GRADE
  7. Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in GRADE
  8. Extension Study of the DiRECT Trial of Continued Support for Weight Loss Maintenance in the UK
  9. Cardiovascular Outcomes Associated With Glucose-Lowering Medications in Patients With Type 2 Diabetes
  10. 2023 Top Story in Diabetes: The STEP-HFpEF Trial

Elsewhere

Most Read This Week

Recently Updated